Kiniksa Pharmaceuticals Ltd expected to post a loss of 7 cents a share - Earnings Preview

Kiniksa Pharmaceuticals International

19/07/2024 14:15

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ   KNSA.O  is expected
to show a rise in quarterly revenue when it reports  results on
July 23 for the period ending June 30 2024
    * The Hamilton Bermuda-based   company is expected to report
a
29.2% increase in revenue to $92.313 million from $71.47 million
a year ago, according to the mean estimate from 2 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Kiniksa Pharmaceuticals
Ltd is
for a loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $30.00​, above​ its last closing price
of $21.16. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.16       -0.16      -0.25     Missed  -53.1
 Dec. 31 2024  -0.12       -0.14      0.35      Beat    350
 Sep. 30 2023  -0.17       -0.17      -0.20     Missed  -19.4​
 Jun. 30 2023  -0.17       -0.17      0.21      Beat    225.4
 ​​Dec.        -0.22       -0.21      -0.18     Beat    13.3
 31 2022                                                
 Dec. 31 2022  -0.23       -0.23      0.06      Beat    125.8​
 Sep. 30 2022  0.79        0.78       3.18      Beat    306.4
 Jan. 1 0001   -0.45       -0.44      -0.29     Beat    34.5
 This summary was machine generated July 19 at 13:15 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)